Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
---|---|
Information provided by: | National Institutes of Health Clinical Center (CC) |
ClinicalTrials.gov Identifier: | NCT00492531 |
This study will examine whether the drug sildenafil can lower blood pressure in the pulmonary artery (the blood vessel that leads from the heart to the lungs) in patients with sickle cell disease and pulmonary hypertension (high blood pressure in the lungs). It will see if this treatment can reduce disease complications, such as shortness of breath, pain crisis, pneumonia, and increase survival.
Patients 12 years of age and older with sickle cell disease and pulmonary hypertension may be eligible for this study. Participants are randomly assigned to receive sildenafil or placebo (sugar pill) for 16 weeks. Before starting treatment, patients have baseline studies, including a pregnancy test for females of childbearing age; a chest x-ray; pulmonary function tests to measure how much air the patient can breathe in and out; an echocardiogram (heart ultrasound); a 6-minute walk test to measure exercise capacity; a quality-of-life assessment and a pain inventory. Patients with moderate to severe pulmonary hypertension undergo heart catheterization to evaluate the severity of hypertension before beginning sildenafil therapy.
During treatment, patients are monitored with the following:
At the end of the 16-week period, patients may opt to continue to receive sildenafil and monitoring in an open-label phase of the study for up to 1 year.
Condition | Intervention | Phase |
---|---|---|
Sickle Cell Disease Pulmonary Hypertension |
Drug: Sildenafil Drug: Placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Treatment of Pulmonary Hypertension and Sickle Cell Disease With Sildenafil Therapy |
Estimated Enrollment: | 1000 |
Study Start Date: | June 2007 |
Arms | Assigned Interventions |
---|---|
1: Experimental
TRV greater than or equal to 2.7 but less than 3.0
|
Drug: Sildenafil
Administered on an escalating scale of 20, 40, 80 mg, orally, 3 times daily for 16 weeks.
|
2: Placebo Comparator
TRV greater than or equal to 2.7 but less than 3.0
|
Drug: Placebo
Administered on an escalating scale of 20, 40, 80 mg, orally, 3 times daily for 16 weeks.
|
3: Experimental
TRV greater than or equal to 3.0
|
Drug: Sildenafil
Administered on an escalating scale of 20, 40, 80 mg, orally, 3 times daily for 16 weeks.
|
4: Placebo Comparator
TRV greater than or equal to 3.0
|
Drug: Placebo
Administered on an escalating scale of 20, 40, 80 mg, orally, 3 times daily for 16 weeks.
|
Sickle cell disease (SCD) is an autosomal recessive disorder and the most common genetic disease affecting African-Americans. Approximately 0.15 percent of African-Americans are homozygous for sickle cell disease, and 8 percent have sickle cell trait. Acute pain crisis, acute chest syndrome (ACS), and pulmonary hypertension are common complications of sickle cell anemia. Pulmonary hypertension (PH) has now been identified as a marker of mortality in adults with sickle cell disease. Sildenafil has been proven beneficial in pulmonary hypertension (PH) and recent phase I/II studies from the intramural National Institutes of Health (NIH) suggest it is well tolerated and efficacious in the SCD population. Furthermore, a number of recent studies have suggested that nitric oxide (NO) based therapies may have a favorable impact on sickle red cells at the molecular level and could improve the abnormal microvascular perfusion that is characteristic of sickle cell anemia.
The project has 3 distinct components:
Ages Eligible for Study: | 12 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
INCLUSION CRITERIA:
Screening Phase:
Observational Follow-up Study:
Main Interventional Trial:
EXCLUSION CRITERIA:
Current pregnancy or lactation.
Any one of the following medical conditions:
Subjects taking nitrate-based vasodilators (including, but not limited to nicorandil [available in the UK only]), prostacyclin (inhaled, subcutaneous or intravenous) or endothelin antagonists. Subjects taking calcium channel blockers will be allowed to participate provided they are on a stable dose for greater than or equal to 3 months.
Left ventricular ejection fraction less than 40 percent or clinically significant ischemic, valvular or constrictive heart disease: LVEF less than 40 percent or SF less than 22 percent.
Subjects who are in other research studies with investigational drugs with the exception of hydroxyurea unless the other trial has been approved by the walk-PHaSST Executive Committee for co-participation.
Acute or chronic impairment (other than dyspnea), limiting the ability to comply with study requirements (in particular with 6MWT), e.g., angina pectoris, intermittent claudication, symptomatic hip osteonecrosis.
Tonsillectomies for sleep apnea within 3 months prior to randomization.
Active therapy for pulmonary hypertension, including prostacyclin analog, endothelin-1 antagonists, or PDE-5 inhibitor.
Protease inhibitor therapy for the treatment of HIV.
Subjects taking potent CYP3A4 inhibitor therapy (e.g., itraconazole, ritonavir, ketoconazole)
Subjects who are antigoagulated and have proliferative retinopathy (unless they have had ophthalmologist recommended intervention (e.g., phototherapy) or have been otherwise cleared by the ophthalmologist to participate in the study.
Contact: Patient Recruitment and Public Liaison Office | (800) 411-1222 | prpl@mail.cc.nih.gov |
Contact: TTY | 1-866-411-1010 |
United States, California | |
Children's Hospital, Oakland | Recruiting |
Oakland, California, United States, 94609 | |
United States, Colorado | |
University of Colorado | Recruiting |
Denver, Colorado, United States, 80220-3706 | |
United States, District of Columbia | |
Howard University Hospital | Recruiting |
Washington, District of Columbia, United States, 20060 | |
United States, Illinois | |
University of Illinois at Chicago | Recruiting |
Chicago, Illinois, United States, 60612 | |
United States, Maryland | |
National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting |
Bethesda, Maryland, United States, 20892 | |
Johns Hopkins University | Recruiting |
Baltimore, Maryland, United States, 21205 | |
United States, New York | |
Albert Einstein College of Medicine | Recruiting |
Bronx, New York, United States, 10461 | |
United States, Pennsylvania | |
Childrens Hospital, Pittsburgh | Recruiting |
Pittsburgh, Pennsylvania, United States, 15213-2583 | |
United Kingdom | |
Imperial College London and Hammersmith Hospital | Recruiting |
London, United Kingdom |
Responsible Party: | National Institutes of Health ( Mark T. Gladwin, M.D./National Heart, Lung, and Blood Institute ) |
Study ID Numbers: | 070177, 07-H-0177 |
Study First Received: | June 26, 2007 |
Last Updated: | November 21, 2008 |
ClinicalTrials.gov Identifier: | NCT00492531 |
Health Authority: | United States: Federal Government |
Interventional Study 6-Minute Walk Sickle Cell Anemia Sildenafil/Viagra |
Tricuspid Regurgitant Velocity Sickle Cell Disease Pulmonary Hypertension |
Hematologic Diseases Anemia Vascular Diseases Anemia, Hemolytic Sildenafil Sickle cell anemia Anemia, Hemolytic, Congenital Genetic Diseases, Inborn |
Respiratory Tract Diseases Hypertension, Pulmonary Hemoglobinopathies Lung Diseases Hemoglobinopathy Anemia, Sickle Cell Hypertension |
Vasodilator Agents Phosphodiesterase Inhibitors Molecular Mechanisms of Pharmacological Action Therapeutic Uses |
Enzyme Inhibitors Cardiovascular Diseases Cardiovascular Agents Pharmacologic Actions |